DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

Barclays Initiates Coverage On Fate Therapeutics with Overweight Rating, Announces $40 Price Target

Barclays analyst Peter Lawson initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Overweight rating and a $40 price target.

Benzinga · 03/04/2020 10:22

Barclays analyst Peter Lawson initiates coverage on Fate Therapeutics (NASDAQ:FATE) with a Overweight rating and a $40 price target.